Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ropinirole dosing for up to 28 days · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ropinirole dosing for up to 28 days | DRUG | - |
Inclusion: * Patients and subjects between 18-79 years old. * End stage renal patients who are consistently receiving dialysis for a minimum of 3.5 hours, three times per week, with hemodialysis blood flow rates of \>200mL/min may be eligible to enter the study. * Patients must also have systolic b...
Ropinirole dosing for up to 28 days is used for Restless Legs Syndrome, a neurological condition. It is a small molecule being studied in a Phase 1 clinical trial to investigate the effects of end stage renal disease and hemodialysis on the pharmacokinetics of ropinirole.
Ropinirole dosing for up to 28 days is developed by GSK plc, which trades under the ticker GSK. The company is conducting a Phase 1 clinical trial for this small molecule intended for Restless Legs Syndrome.
Ropinirole dosing for up to 28 days is in Phase 1 clinical development. It is an investigational drug for Restless Legs Syndrome, and the single clinical trial listed for it has been completed. It is not approved by the FDA.
Ropinirole dosing for up to 28 days has one completed clinical trial, NCT00422994, titled 'A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole'. This Phase 1 trial enrolled 48 participants with Restless Legs Syndrome in the United States and United Kingdom.
Ropinirole dosing for up to 28 days is a formulation or dosing regimen of ropinirole, a small molecule used for Restless Legs Syndrome. The clinical trial NCT00422994 investigates the pharmacokinetics of ropinirole in patients with end stage renal disease undergoing hemodialysis.